WallStreetZenWallStreetZen

NASDAQ: OBX
Obsidian Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Should I buy or sell OBX stock?

Based on 1 analyst offering ratings for Obsidian Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although OBX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates OBX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their OBX stock forecasts and price targets.

OBX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-22
lockedlocked$00.00+00.00%2026-09-09

1 of 1

Forecast return on equity

Is OBX forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is OBX forecast to generate an efficient return on assets?

Company
-432.38%
Industry
-4.33%
OBX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

OBX earnings per share forecast

What is OBX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$2.55
Avg 2 year Forecast
-$2.76
Avg 3 year Forecast
-$3.60

OBX revenue forecast

What is OBX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

OBX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
OBX$12.86N/AN/ABuy
LXRX$1.80$3.10+72.70%Strong Buy
FDMT$14.47$28.50+96.96%Strong Buy
IMMX$10.97$23.50+114.22%Strong Buy
SLDB$7.29$20.50+181.21%Strong Buy
View Top Biotech Stocks

Obsidian Therapeutics Stock Forecast FAQ

Is Obsidian Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: OBX) stock is to Buy OBX stock.

Out of 1 analyst, 0 (0%) are recommending OBX as a Strong Buy, 1 (100%) are recommending OBX as a Buy, 0 (0%) are recommending OBX as a Hold, 0 (0%) are recommending OBX as a Sell, and 0 (0%) are recommending OBX as a Strong Sell.

If you're new to stock investing, here's how to buy Obsidian Therapeutics stock.

What is OBX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: OBX) Obsidian Therapeutics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that OBX's EPS will be -$2.55 for 2026, with the lowest EPS forecast at -$3.87, and the highest EPS forecast at -$1.05. On average, analysts forecast that OBX's EPS will be -$2.76 for 2027, with the lowest EPS forecast at -$3.77, and the highest EPS forecast at -$2.24. In 2028, OBX's EPS is forecast to hit -$3.60 (min: -$4.31, max: -$2.87).

What is OBX's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: OBX) forecast ROE is N/A, which is considered weak.

What is OBX's earnings growth forecast for 2026-2028?

(NASDAQ: OBX) Obsidian Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 63.61%.

Obsidian Therapeutics's earnings in 2026 is N/A.On average, 4 Wall Street analysts forecast OBX's earnings for 2026 to be -$157,434,352, with the lowest OBX earnings forecast at -$239,122,803, and the highest OBX earnings forecast at -$64,861,520. On average, 4 Wall Street analysts forecast OBX's earnings for 2027 to be -$170,740,229, with the lowest OBX earnings forecast at -$233,069,061, and the highest OBX earnings forecast at -$138,155,037.

In 2028, OBX is forecast to generate -$222,425,595 in earnings, with the lowest earnings forecast at -$266,364,641 and the highest earnings forecast at -$177,071,949.

What is OBX's revenue growth forecast for 2026-2028?

(NASDAQ: OBX) Obsidian Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 43.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.28%.

Obsidian Therapeutics's revenue in 2026 is N/A.On average, 4 Wall Street analysts forecast OBX's revenue for 2026 to be $0, with the lowest OBX revenue forecast at $0, and the highest OBX revenue forecast at $0. On average, 4 Wall Street analysts forecast OBX's revenue for 2027 to be $0, with the lowest OBX revenue forecast at $0, and the highest OBX revenue forecast at $0.

In 2028, OBX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is OBX's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: OBX) forecast ROA is -432.38%, which is lower than the forecast US Biotechnology industry average of -4.33%.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.